IMG-008 / ImageneBio - LARVOL DELTA

IMG-008, a potent anti-human IL-36R antagonistic antibody, inhibits IL-36R-mediated inflammation (ISID 2023) - "The inhibition activity was comparable to spesolimab analog and superior to imsidolimab analog. Administration of IMG-008 suppressed imiquimod induced skin inflammation in hIL-36R mice, which was superior to spesolimab analog... IMG-008 exhibited potent IL-36R blocking activity from in vitro assays and in vivo skin inflammation animal model. In addition, IMG-008 has improved drug exposure and extended half-life. In conclusion, our preclinical results support IMG-008 as a promising candidate for treating IL-36R mediated inflammatory disease."

Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hidradenitis Suppurativa • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis

Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb (PRNewswire) - "Inmagene Biopharmaceuticals...announced that the U.S. Food and Drug Administration (FDA) recently granted the initial investigational new drug (IND) application for its drug candidate IMG-008, a long-acting anti-IL-36R antibody with enhanced half-life and exposure....The proposed IND-opening study is a randomized, double-blind, placebo-controlled dose escalation Phase I study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of IMG-008 in healthy adult subjects."

IND • Immunology • Inflammatory Bowel Disease

Inmagene files two international patent applications (PRNewswire) - "Inmagene Biopharmaceuticals...announced that it has filed two international patent applications for its drug candidates, IMG-007 (OX40 antagonist) and IMG-008 (IL-36R antagonist). One application covers IMG-008's molecular sequence and the other covers improved development in IMG-007's formulation...IMG-007, in-licensed from HUTCHMED (Nasdaq/AIM: HCM), is under CMC and toxicological development and the Company plans to submit IMG-007's IND application by the first half of 2022...The Company plans to submit IMG-008's IND application in the second half of 2022."

IND • Patent • Inflammatory Bowel Disease